MRSN [NASD]
Mersana Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.49 Insider Own0.50% Shs Outstand79.93M Perf Week17.11%
Market Cap322.65M Forward P/E- EPS next Y-2.07 Insider Trans- Shs Float53.31M Perf Month-10.97%
Income-182.60M PEG- EPS next Q-0.54 Inst Own78.90% Short Float8.03% Perf Quarter-9.82%
Sales2.10M P/S153.64 EPS this Y-68.30% Inst Trans6.85% Short Ratio2.75 Perf Half Y-57.49%
Book/sh1.76 P/B1.98 EPS next Y-10.00% ROA-78.10% Target Price18.00 Perf Year-75.16%
Cash/sh- P/C- EPS next 5Y- ROE-119.10% 52W Range2.68 - 15.34 Perf YTD-43.89%
Dividend- P/FCF- EPS past 5Y-31.80% ROI- 52W High-77.25% Beta2.37
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low30.22% ATR0.35
Employees169 Current Ratio4.30 Sales Q/Q0.00% Oper. Margin- RSI (14)48.14 Volatility7.91% 9.37%
OptionableYes Debt/Eq0.00 EPS Q/Q-17.60% Profit Margin- Rel Volume0.93 Prev Close3.45
ShortableYes LT Debt/Eq0.18 EarningsMay 09 BMO Payout- Avg Volume1.56M Price3.49
Recom1.60 SMA200.29% SMA50-10.48% SMA200-49.18% Volume1,453,409 Change1.16%
Oct-15-21Resumed BTIG Research Buy $32
Aug-30-21Initiated H.C. Wainwright Buy $28
Mar-31-21Initiated Credit Suisse Neutral $18
Dec-03-20Initiated Stifel Buy $33
Sep-29-20Resumed JP Morgan Neutral $20
Apr-29-20Initiated BTIG Research Buy $14
Jan-21-20Reiterated H.C. Wainwright Buy $7 → $12
Mar-11-19Downgrade JP Morgan Neutral → Underweight
Nov-14-18Upgrade Leerink Partners Mkt Perform → Outperform
May-08-18Initiated Robert W. Baird Outperform
Mar-19-18Downgrade JP Morgan Overweight → Neutral
May-19-22 07:00AM  
May-09-22 08:25AM  
07:00AM  
May-06-22 04:05PM  
May-02-22 08:00AM  
Apr-06-22 04:05PM  
Apr-05-22 08:00AM  
Mar-30-22 06:40AM  
Mar-15-22 08:00AM  
Mar-02-22 08:00AM  
Feb-28-22 07:15AM  
06:00AM  
Feb-24-22 05:20PM  
08:38AM  
Feb-22-22 08:00AM  
Feb-18-22 05:07PM  
Feb-10-22 08:00AM  
Feb-03-22 01:39PM  
07:00AM  
Jan-07-22 08:00AM  
Jan-06-22 04:34PM  
Jan-05-22 08:57PM  
08:00AM  
Dec-02-21 08:00AM  
Nov-23-21 08:00AM  
Nov-10-21 08:00AM  
Nov-09-21 07:15AM  
06:00AM  
Nov-02-21 08:00AM  
Nov-01-21 03:01PM  
Oct-27-21 04:05PM  
Oct-25-21 08:00AM  
Oct-18-21 04:35AM  
Oct-08-21 12:52PM  
Oct-07-21 04:05PM  
Sep-30-21 08:00AM  
Sep-13-21 04:20PM  
Sep-07-21 08:00AM  
Sep-01-21 08:00AM  
Aug-18-21 04:05PM  
Aug-16-21 08:00AM  
Aug-06-21 06:00AM  
Jul-30-21 08:00AM  
Jul-28-21 08:00AM  
Jul-13-21 10:41AM  
Jun-29-21 11:13AM  
Jun-05-21 04:41AM  
May-28-21 11:35AM  
May-26-21 08:00AM  
May-10-21 05:45PM  
04:01PM  
02:30PM  
May-03-21 08:00AM  
Apr-28-21 04:05PM  
Apr-26-21 08:00AM  
Apr-19-21 05:24PM  
Apr-10-21 09:00AM  
Apr-09-21 10:17AM  
08:15AM  
08:00AM  
Mar-15-21 10:15AM  
Mar-12-21 06:02AM  
Mar-11-21 08:00AM  
Mar-10-21 04:35PM  
Mar-09-21 07:30AM  
Mar-04-21 07:30AM  
Feb-26-21 07:30AM  
06:15AM  
06:00AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Jan-22-21 08:00AM  
Jan-19-21 08:00AM  
Jan-06-21 08:00AM  
Jan-05-21 01:08PM  
10:00AM  
Jan-04-21 04:05PM  
Dec-30-20 10:42AM  
Dec-25-20 03:06AM  
Dec-17-20 08:00AM  
Dec-10-20 10:33PM  
Dec-04-20 04:05PM  
09:57AM  
Dec-02-20 04:05PM  
Nov-30-20 08:00AM  
Nov-25-20 07:30AM  
Nov-24-20 04:01PM  
Nov-19-20 07:00PM  
Nov-18-20 04:02PM  
Nov-12-20 07:38AM  
Nov-11-20 09:00AM  
Nov-10-20 06:37AM  
Nov-09-20 07:30AM  
07:30AM  
06:15AM  
06:00AM  
Nov-05-20 10:51AM  
Nov-04-20 08:00AM  
Nov-02-20 08:00AM  
07:30AM  
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hack Andrew A. F.DirectorMay 18Buy3.35211,268707,2628,087,400May 18 06:19 PM
Hack Andrew A. F.DirectorMay 17Buy3.183,44010,9527,876,132May 18 06:19 PM
Hack Andrew A. F.DirectorMay 16Buy3.10135,292419,4467,872,692May 18 06:19 PM
Carvajal AlejandraChief Legal OfficerApr 26Option Exercise0.0013,250013,250Apr 28 05:23 PM
Carvajal AlejandraChief Legal OfficerApr 26Sale3.693,94814,5689,302Apr 28 05:23 PM
Hack Andrew A. F.DirectorApr 13Buy4.05617,2842,500,0007,737,400Apr 14 04:59 PM
Hack Andrew A. F.DirectorApr 12Buy4.18598,0862,499,8807,120,116Apr 13 06:27 PM
Hack Andrew A. F.DirectorFeb 07Buy4.421,136,3635,022,7246,522,030Feb 08 05:04 PM
Lowinger Timothy BChief Science & Tech Off.Jan 18Sale5.924,74128,067131,234Jan 19 06:25 PM
Mandelia AshishVP, ControllerJan 18Sale5.921,98211,7333,371Jan 19 06:19 PM
Hack Andrew A. F.DirectorDec 30Buy6.15815,0005,012,2505,385,667Jan 04 06:16 PM
Hack Andrew A. F.DirectorDec 29Buy5.75875,0005,031,2504,570,667Jan 03 06:28 PM
Lowinger Timothy BChief Science & Tech. OfficerDec 20Option Exercise1.4045,59363,830120,766Dec 20 05:01 PM
Yang ArvinChief Medical OfficerDec 01Sale6.815,52737,63912,973Dec 02 05:00 PM
Lowinger Timothy BChief Science & Tech. OfficerAug 20Option Exercise6.162,21613,65177,389Aug 24 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerAug 20Sale11.012,21624,39875,173Aug 24 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerJul 20Option Exercise6.162,22713,71877,400Jul 22 04:32 PM
Lowinger Timothy BChief Science & Tech. OfficerJul 20Sale12.112,22726,96975,173Jul 22 04:32 PM
Lowinger Timothy BChief Science & Tech. OfficerJul 19Sale12.028,496102,12275,173Jul 19 08:50 PM
Kaufman Michael J.Chief Manufacturing OfficerJul 19Sale12.026,31275,87032,622Jul 19 08:50 PM
Protopapas AnnaPresident & CEOJul 19Sale12.0221,901263,250282,978Jul 19 08:49 PM
Protopapas AnnaPresident & CEOJul 16Sale12.4720,043249,936304,879Jul 19 08:49 PM
Kaufman Michael J.Chief Manufacturing OfficerJul 16Sale12.475,77672,02738,934Jul 19 08:50 PM
Lowinger Timothy BChief Science & Tech. OfficerJul 16Sale12.477,77596,95483,669Jul 19 08:50 PM
Lowinger Timothy BCS & Technology OfficerJul 08Option Exercise1.4020,00028,00051,444Jul 09 05:25 PM
Lowinger Timothy BCS & Technology OfficerJul 01Option Exercise3.521,8866,64433,330Jul 02 04:32 PM
Lowinger Timothy BCS & Technology OfficerJul 01Sale13.601,88625,65031,444Jul 02 04:32 PM
Lowinger Timothy BChief Science & Tech. OfficerJun 21Option Exercise6.162,22013,67033,662Jun 23 04:30 PM
Lowinger Timothy BChief Science & Tech. OfficerJun 21Sale13.782,22030,59231,444Jun 23 04:30 PM
Alleva Lawrence MDirectorJun 01Buy14.381,03514,8832,120Jun 03 06:58 PM